

## THE R.W. JOHNSON

PHARMACEUTICAL RESEARCH INSTITUTE AND AUG 22 2 2000 ROUTE 202, P.O. BOX 300, RARITAN, NEW JERSEY 08869-0602

**RE: DOCKET NO. 00D-1350** 

Comment to Draft Guidance

Dockets Management Branch (HFA-305) Food and Drug Adminstration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

## Dear Sir or Madame:

Reference is made to the draft guidance entitled "Combined Oral Contraceptives-Labeling for Healthcare Providers and Patients". The R.W. Johnson Pharmaceutical Research Institute (RWJPRI), an affiliate of the Johnson & Johnson family of companies, would like to request a 30-day extension for submitting comments to this draft guidance document. RWJPRI and Johnson & Johnson sponsor many women's health care products and we have been working diligently to provide our comments to this important guidance document. We hope that you can grant us this extension to the September 8, 2000 deadline.

If you have any questions or require any additional information, please contact me directly at (908) 704-4812, Terri Williams at (908) 429-1896, or at our phone number designated for FDA use (908) 704-4600.

Sincerely,

Ramon Polo, PhD

Director

Regulatory Affairs

000-1350

LA JOLLA **RARITAN** SPRING HOUSE **ZURICH** 

## Express Federal

## Align top of FedEx PowerShip Label here.

Roger Claringbold R W JOHNSON PRI 920 ROUTE 202 SOUTH RARLIAN

TO: FOOD AND DRUG ADMINISTRATION DOCKETS MANAGEMENT BRANCH (HFA-305)

5630 FISHERS LAME, ROOM 1061

ROCKUILLE

20857

4108 3561 8474 **Fed E**XX.

REF: DOCKT# 000-1350

PRIORITY OVERNIGHT

cad # 0003720 22AUG00

4108 3561 8474

Deliver by:



The World On Time